CoChat

Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma

Open access

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Abstract

The tumor microenvironment is deeply involved in the process of tumor growth and development. In this study, we focused on cancer-associated fibroblasts (CAFs) and their derived exosomes on the lymphoma microenvironment to uncover their clinical significance. CAFs were established from primary lymphoma samples, and exosomes secreted from CAFs were obtained by standard procedures. We then investigated the roles of CAFs and their derived exosomes in the survival and drug resistance of lymphoma cells. CAFs supported the survival of lymphoma cells through increased glycolysis, and the extent differed among CAFs. Exosomes were identified as a major component of the extracellular vesicles from CAFs, and they also supported the survival of lymphoma cells. The suppression of RAB27B, which is involved in the secretion of exosomes, using a specific siRNA resulted in reduced exosome secretion and decreased survival of lymphoma cells. Moreover, anti-pyrimidine drug resistance was induced in the presence of exosomes through the suppression of the pyrimidine transporter, equilibrative nucleoside transporter 2 (ENT2), and the suppression of ENT2 was significant in in vivo experiments and clinical samples. RNA sequencing analysis of miRNAs in exosomes identified miR-4717-5p as one of the most abundant miRNAs in the exosome, which suppressed the expression of ENT2 and induced anti-pyrimidine drug resistance in vitro. Our results suggest that exosomes including miR-4717-5p secreted from CAFs play a pivotal role in the lymphoma microenvironment, indicating that they are a promising therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-021-01829-y

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Diversity of survival of lymphoma cells with CAFs. A Phase-contrast images and the expression of α-SMA via FCM of CAF1, CAF2, CAF3, and CAF4. B Viability of HGBL-NOS cells co-cultured with each CAF. CAFs that displayed strong improvement of HGBL-NOS survival (CAF1 and CAF2) (red circles) and weak improvement (CAF3 and CAF4) (blue circles) and high proliferation potential were selected. Each point represents the viability of HGBL-NOS cells co-cultured with each CAF, and the bar represents the mean value. C Viability of tumor cells from patients diagnosed with HGBL-NOS in monoculture and co-culture with CAF1 to CAF4. D Viability of tumor cells from patients diagnosed with BL in monoculture and co-culture with CAF1 to CAF4. E Immunoblotting for HK2, PDK1, and tubulin as a loading control in HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4. F Relative ATP concentrations of HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ***0.001 > p ≥ 0.0001, ****<0.0001. Each bar is the mean value taken from 3 or more independent experiments with error bars indicating standard error. Ns, not significant.
Fig. 1 Diversity of survival of lymphoma cells with CAFs. A Phase-contrast images and the expression of α-SMA via FCM of CAF1, CAF2, CAF3, and CAF4. B Viability of HGBL-NOS cells co-cultured with each CAF. CAFs that displayed strong improvement of HGBL-NOS survival (CAF1 and CAF2) (red circles) and weak improvement (CAF3 and CAF4) (blue circles) and high proliferation potential were selected. Each point represents the viability of HGBL-NOS cells co-cultured with each CAF, and the bar represents the mean value. C Viability of tumor cells from patients diagnosed with HGBL-NOS in monoculture and co-culture with CAF1 to CAF4. D Viability of tumor cells from patients diagnosed with BL in monoculture and co-culture with CAF1 to CAF4. E Immunoblotting for HK2, PDK1, and tubulin as a loading control in HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4. F Relative ATP concentrations of HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ***0.001 > p ≥ 0.0001, ****<0.0001. Each bar is the mean value taken from 3 or more independent experiments with error bars indicating standard error. Ns, not significant.CC BY · PubMed Central
Fig. 2 Extracellular vesicles from CAFs. A Electron microscopic images of extracellular vesicles from each CAF. Scale bar, 200 nm. B Immunoblotting for CD9 and CD63 for each CAF. C Nanoparticle tracking analysis for CAF1, CAF2, CAF3, and CAF4.
Fig. 2 Extracellular vesicles from CAFs. A Electron microscopic images of extracellular vesicles from each CAF. Scale bar, 200 nm. B Immunoblotting for CD9 and CD63 for each CAF. C Nanoparticle tracking analysis for CAF1, CAF2, CAF3, and CAF4.CC BY · PubMed Central
Fig. 3 Survival of lymphoma cells in the presence of exosomes from CAFs. A Fluorescent microscopic image of exosomes stained with PKH26 (red), tumor cells stained with Hoechst 33342 (blue), and a merged image. B Viability of HGBL-NOS cells in monoculture and in the presence of exosomes from each CAF. Ten thousand tumor cells were seeded in 96-well plates with 0.8 × 109 exosomes, and then viability was evaluated after 48-h incubation. C Viability of BL cells in monoculture and in the presence of exosomes from each CAF. The conditions were the same as in (B). D Immunoblotting for HK2, PDK1, and tubulin as a loading control in HGBL-NOS cells in monoculture and in the presence of exosomes. Three hundred thousand tumor cells were seeded in 6-well plates with 2.4 × 1010 exosomes, and then proteins were obtained after 24-h incubation. E Relative ATP concentrations of HGBL-NOS cells in the presence of exosomes from each CAF. Three hundred thousand tumor cells were seeded in 6-well plates with 2.4 × 1010 exosomes, and then assays were performed after 24-h incubation. F Viability of HGBL-NOS cells in the presence of various concentrations of exosomes from CAF1. The highest exosome concentration was 2.5 × 1010 particles/ml and was serially diluted 2-fold to give a concentration gradient. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001. Each bar is the mean value taken from 3 or more independent experiments with error bars indicating standard error. Ns, not significant.
Fig. 3 Survival of lymphoma cells in the presence of exosomes from CAFs. A Fluorescent microscopic image of exosomes stained with PKH26 (red), tumor cells stained with Hoechst 33342 (blue), and a merged image. B Viability of HGBL-NOS cells in monoculture and in the presence of exosomes from each CAF. Ten thousand tumor cells were seeded in 96-well plates with 0.8 × 109 exosomes, and then viability was evaluated after 48-h incubation. C Viability of BL cells in monoculture and in the presence of exosomes from each CAF. The conditions were the same as in (B). D Immunoblotting for HK2, PDK1, and tubulin as a loading control in HGBL-NOS cells in monoculture and in the presence of exosomes. Three hundred thousand tumor cells were seeded in 6-well plates with 2.4 × 1010 exosomes, and then proteins were obtained after 24-h incubation. E Relative ATP concentrations of HGBL-NOS cells in the presence of exosomes from each CAF. Three hundred thousand tumor cells were seeded in 6-well plates with 2.4 × 1010 exosomes, and then assays were performed after 24-h incubation. F Viability of HGBL-NOS cells in the presence of various concentrations of exosomes from CAF1. The highest exosome concentration was 2.5 × 1010 particles/ml and was serially diluted 2-fold to give a concentration gradient. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001. Each bar is the mean value taken from 3 or more independent experiments with error bars indicating standard error. Ns, not significant.CC BY · PubMed Central
Fig. 4 Amounts of exosome secretion from each CAF. A Number of particles secreted from each CAF as measured by NTA. B Immunoblotting for nSMase2 and tubulin in each CAF. C Immunoblotting for RAB27B and tubulin in each CAF. D, E Immunoblotting for RAB27B and tubulin in CAF1 and CAF2 transfected with siRNA as indicated. F, G Number of particles secreted from CAF1 and CAF2 transfected with siRNA as indicated. H–K Viability of HGBL-NOS and BL cells co-cultured with CAFs transfected with siRNA as indicated. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001. Each bar is the mean taken from three or more independent experiments with error bars indicating standard error. Ns, not significant.
Fig. 4 Amounts of exosome secretion from each CAF. A Number of particles secreted from each CAF as measured by NTA. B Immunoblotting for nSMase2 and tubulin in each CAF. C Immunoblotting for RAB27B and tubulin in each CAF. D, E Immunoblotting for RAB27B and tubulin in CAF1 and CAF2 transfected with siRNA as indicated. F, G Number of particles secreted from CAF1 and CAF2 transfected with siRNA as indicated. H–K Viability of HGBL-NOS and BL cells co-cultured with CAFs transfected with siRNA as indicated. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001. Each bar is the mean taken from three or more independent experiments with error bars indicating standard error. Ns, not significant.CC BY · PubMed Central
Fig. 5 Change of susceptibility to anti-pyrimidine drugs induced by CAFs and their derived exosomes. A Viability of HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4 in the presence of 10 nM gemcitabine. B Immunoblotting for cleaved caspase-3 and tubulin as a loading control in HGBL-NOS cells in the above conditions. C Susceptibility of HGBL-NOS cells to gemcitabine. Assessment of cell death of HGBL-NOS cells in monoculture and co-culture with each CAF is shown. D Relative viability of HGBL-NOS cells to 10 nM gemcitabine in the presence of exosomes from CAF1 and CAF2. Ten thousand tumor cells were seeded in 96-well plates with 5.0 × 109 exosomes and gemcitabine, and then viability was evaluated after 48-h incubation. E Immunoblotting for cleaved caspase-3 and tubulin as a loading control in HGBL-NOS cells in the presence of 10 nM gemcitabine. Three hundred thousand tumor cells were seeded in 6-well plates with 1.5 × 1011 exosomes, and proteins were obtained after 24-h incubation. F Assessment of cell death of HGBL-NOS cells treated with 10 nM gemcitabine in the presence of exosomes from CAF1 and CAF2. The conditions were the same as in (E). Cell death was evaluated after 48-h incubation. G Cell death of HGBL-NOS cells co-cultured with CAF1 transfected with siRNA for RAB27B. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ***0.001 > p ≥ 0.0001. Each bar is the mean taken from three or more independent experiments with error bars indicating standard error.
Fig. 5 Change of susceptibility to anti-pyrimidine drugs induced by CAFs and their derived exosomes. A Viability of HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4 in the presence of 10 nM gemcitabine. B Immunoblotting for cleaved caspase-3 and tubulin as a loading control in HGBL-NOS cells in the above conditions. C Susceptibility of HGBL-NOS cells to gemcitabine. Assessment of cell death of HGBL-NOS cells in monoculture and co-culture with each CAF is shown. D Relative viability of HGBL-NOS cells to 10 nM gemcitabine in the presence of exosomes from CAF1 and CAF2. Ten thousand tumor cells were seeded in 96-well plates with 5.0 × 109 exosomes and gemcitabine, and then viability was evaluated after 48-h incubation. E Immunoblotting for cleaved caspase-3 and tubulin as a loading control in HGBL-NOS cells in the presence of 10 nM gemcitabine. Three hundred thousand tumor cells were seeded in 6-well plates with 1.5 × 1011 exosomes, and proteins were obtained after 24-h incubation. F Assessment of cell death of HGBL-NOS cells treated with 10 nM gemcitabine in the presence of exosomes from CAF1 and CAF2. The conditions were the same as in (E). Cell death was evaluated after 48-h incubation. G Cell death of HGBL-NOS cells co-cultured with CAF1 transfected with siRNA for RAB27B. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ***0.001 > p ≥ 0.0001. Each bar is the mean taken from three or more independent experiments with error bars indicating standard error.CC BY · PubMed Central
Fig. 6 Susceptibility to anti-cancer drugs induced by CAFs and their derived exosomes. A Viability of HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4 in the presence of 100 nM cytarabine. B Relative viability of HGBL-NOS cells. Assessment of cell death of HGBL-NOS cells to cytarabine in the presence of exosomes from CAF1 and CAF2 is shown. C–E Relative viabilities of HGBL-NOS cells to 25 μM bendamustine (C), 100 nM doxorubicin (D), and 5 nM vincristine (E) in the presence of exosomes from CAF1 and CAF2. Ten thousand tumor cells were seeded in 96-well plates with 5.0 × 109 exosomes, and then viability was evaluated after 48-h incubation. F, G Relative viability of representative FL cell lines and DLBCL cell lines exposed to gemcitabine (20 nM in SU-DHL4, SU-DHL6, and OCI-Ly10, and 1 nM in OCI-Ly3) (F) and cytarabine (1250 nM in SU-DHL4 and SU-DHL6, 25 nM in OCI-Ly3, and 1000 nM in OCI-Ly10) (G) in the presence of CAF1- and CAF4-derived exosomes. One hundred and twenty-five thousand tumor cells were seeded in 96-well plates with 8.0 × 109/mL particles of exosomes, and then viability was evaluated after 48-h incubation. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ***0.001 > p ≥ 0.0001, ****<0.0001. Each bar is the mean taken from three or more independent experiments with error bars indicating standard error. Ns, not significant.
Fig. 6 Susceptibility to anti-cancer drugs induced by CAFs and their derived exosomes. A Viability of HGBL-NOS cells in monoculture and co-culture with CAF1 to CAF4 in the presence of 100 nM cytarabine. B Relative viability of HGBL-NOS cells. Assessment of cell death of HGBL-NOS cells to cytarabine in the presence of exosomes from CAF1 and CAF2 is shown. C–E Relative viabilities of HGBL-NOS cells to 25 μM bendamustine (C), 100 nM doxorubicin (D), and 5 nM vincristine (E) in the presence of exosomes from CAF1 and CAF2. Ten thousand tumor cells were seeded in 96-well plates with 5.0 × 109 exosomes, and then viability was evaluated after 48-h incubation. F, G Relative viability of representative FL cell lines and DLBCL cell lines exposed to gemcitabine (20 nM in SU-DHL4, SU-DHL6, and OCI-Ly10, and 1 nM in OCI-Ly3) (F) and cytarabine (1250 nM in SU-DHL4 and SU-DHL6, 25 nM in OCI-Ly3, and 1000 nM in OCI-Ly10) (G) in the presence of CAF1- and CAF4-derived exosomes. One hundred and twenty-five thousand tumor cells were seeded in 96-well plates with 8.0 × 109/mL particles of exosomes, and then viability was evaluated after 48-h incubation. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ***0.001 > p ≥ 0.0001, ****<0.0001. Each bar is the mean taken from three or more independent experiments with error bars indicating standard error. Ns, not significant.CC BY · PubMed Central
Fig. 7 Expression of an anti-pyrimidine drug transporter and intracellular concentrations of drugs. A Immunoblotting for ENT2 and tubulin as a loading control in HGBL-NOS cells in monoculture and co-culture with each CAF. B Immunoblotting for ENT2 and tubulin as a loading control in HGBL-NOS cells in the presence of exosomes from CAF1 and CAF2. Three hundred thousand tumor cells were seeded in 6-well plates with 15 × 1010 exosomes, and proteins were obtained after 24-h incubation. C, D Intracellular concentrations of GEM-TP (C) and Ara-CTP (D). HGBL-NOS cells in the presence of 200 nM gemcitabine (C) and 200 nM cytarabine (D) in monoculture and co-culture with CAF1 and CAF2 were evaluated. E, F Intracellular concentrations of gemcitabine (E) and cytarabine (F) in HGBL-NOS cells in the presence of exosomes from CAF1 and CAF2. G Immunoblotting for ENT2 and β-actin as a loading control in HGBL-NOS cells transfected with each miRNA (left). Relative expression of ENT2 in immunoblotting (right). H Relative viability of HGBL-NOS cells transfected with each miRNA in the presence of 20 nM gemcitabine and 5 μM cytarabine. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ****<0.0001. Each bar is the mean taken from 3 or more independent experiments with error bars indicating standard error. Ns, not significant.
Fig. 7 Expression of an anti-pyrimidine drug transporter and intracellular concentrations of drugs. A Immunoblotting for ENT2 and tubulin as a loading control in HGBL-NOS cells in monoculture and co-culture with each CAF. B Immunoblotting for ENT2 and tubulin as a loading control in HGBL-NOS cells in the presence of exosomes from CAF1 and CAF2. Three hundred thousand tumor cells were seeded in 6-well plates with 15 × 1010 exosomes, and proteins were obtained after 24-h incubation. C, D Intracellular concentrations of GEM-TP (C) and Ara-CTP (D). HGBL-NOS cells in the presence of 200 nM gemcitabine (C) and 200 nM cytarabine (D) in monoculture and co-culture with CAF1 and CAF2 were evaluated. E, F Intracellular concentrations of gemcitabine (E) and cytarabine (F) in HGBL-NOS cells in the presence of exosomes from CAF1 and CAF2. G Immunoblotting for ENT2 and β-actin as a loading control in HGBL-NOS cells transfected with each miRNA (left). Relative expression of ENT2 in immunoblotting (right). H Relative viability of HGBL-NOS cells transfected with each miRNA in the presence of 20 nM gemcitabine and 5 μM cytarabine. Asterisks indicate p values as follows: *0.05 > p ≥ 0.01, **0.01 > p ≥ 0.001, ****<0.0001. Each bar is the mean taken from 3 or more independent experiments with error bars indicating standard error. Ns, not significant.CC BY · PubMed Central
Fig. 8 CAFs affect ENT2 expression and anti-pyrimidine susceptibility in xenograft models. A ENT2 expression in HGBL-NOS cells with or without CAFs subcutaneously transplanted in the flanks of the xenograft model. Pathological specimens of tumors from HGBL-NOS cells (upper), HGBL-NOS cells with CAF1 (center), and HGBL-NOS cells with CAF2 (lower) were stained with hematoxylin and eosin (left) and ENT2 (right). B Schema of in vivo experiments. After tumors formed up to 300 mm3 from HGBL-NOS cells or HGBL-NOS cells with CAF1, mice were treated with gemcitabine (n = 3 for HGBL-NOS cells with CAF1, n = 4 for HGBL-NOS cells) for 3 days. Untreated mice (n = 4 for HGBL-NOS cells with CAF1, n = 4 for HGBL-NOS cells) were set as controls. Tumor volumes were measured, and mice treated with gemcitabine were killed and analyzed on day 12. Mice untreated were killed on day 9 when the tumor size exceeded 2500 mm3. C Tumor volumes from HGBL-NOS cells with CAF1 (red line) and HGBL-NOS cells (blue line) treated with gemcitabine, and untreated HGBL-NOS cells with CAF1 (orange line) and HGBL-NOS cells (green line). Each point is the mean taken from 3 or 4 mice with error bars indicating standard error. Asterisk indicates p value: **0.01 > p ≥ 0.001. D Photographs of mice injected with HGBL-NOS cells with CAF1 (left) and HGBL-NOS cells (right) after gemcitabine treatment on day 12. E Pathological specimens of 3 tumors [(a) to (c)] from HGBL-NOS cells with CAF1 on day 12. Specimens stained with H&E (left, low power field [LPF]; center right, high power field [HPF]) and TUNEL (center left; LPF, right; HPF) are shown. F Pathological specimens of 4 tumors [(a) to (d)] from HGBL-NOS cells on day 12. Specimens of each tumor stained with H&E (left, LPF; center right, HPF) and TUNEL (center left, LPF; right; HPF) are shown. Original magnifications: LPF ×40 and HPF ×400.
Fig. 8 CAFs affect ENT2 expression and anti-pyrimidine susceptibility in xenograft models. A ENT2 expression in HGBL-NOS cells with or without CAFs subcutaneously transplanted in the flanks of the xenograft model. Pathological specimens of tumors from HGBL-NOS cells (upper), HGBL-NOS cells with CAF1 (center), and HGBL-NOS cells with CAF2 (lower) were stained with hematoxylin and eosin (left) and ENT2 (right). B Schema of in vivo experiments. After tumors formed up to 300 mm3 from HGBL-NOS cells or HGBL-NOS cells with CAF1, mice were treated with gemcitabine (n = 3 for HGBL-NOS cells with CAF1, n = 4 for HGBL-NOS cells) for 3 days. Untreated mice (n = 4 for HGBL-NOS cells with CAF1, n = 4 for HGBL-NOS cells) were set as controls. Tumor volumes were measured, and mice treated with gemcitabine were killed and analyzed on day 12. Mice untreated were killed on day 9 when the tumor size exceeded 2500 mm3. C Tumor volumes from HGBL-NOS cells with CAF1 (red line) and HGBL-NOS cells (blue line) treated with gemcitabine, and untreated HGBL-NOS cells with CAF1 (orange line) and HGBL-NOS cells (green line). Each point is the mean taken from 3 or 4 mice with error bars indicating standard error. Asterisk indicates p value: **0.01 > p ≥ 0.001. D Photographs of mice injected with HGBL-NOS cells with CAF1 (left) and HGBL-NOS cells (right) after gemcitabine treatment on day 12. E Pathological specimens of 3 tumors [(a) to (c)] from HGBL-NOS cells with CAF1 on day 12. Specimens stained with H&E (left, low power field [LPF]; center right, high power field [HPF]) and TUNEL (center left; LPF, right; HPF) are shown. F Pathological specimens of 4 tumors [(a) to (d)] from HGBL-NOS cells on day 12. Specimens of each tumor stained with H&E (left, LPF; center right, HPF) and TUNEL (center left, LPF; right; HPF) are shown. Original magnifications: LPF ×40 and HPF ×400.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 62

Metadata

Authors
Kunou, S., Shimada, K., Takai, M., Sakamoto, A., Aoki, T., Hikita, T., Kagaya, Y., Iwamoto, E., Sanada, M., Shimada, S., Hayakawa, F., Oneyama, C., & Kiyoi, H.
Affiliations
  • Nagoya University (JP)
  • Aichi Cancer Center (JP)
  • National Hospital Organization (JP)
  • Nagoya University Hospital (JP)
Corresponding author
Shimada, Kazuyuki
Venue
Oncogene
Published
2021-05-16
Volume
40
Issue
23
Pages
3989-4003
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W3160330004
Cited by
62
References
35
Citations by year
2026: 7 · 2025: 19 · 2024: 12 · 2023: 11 · 2022: 8 · 2021: 5
FWCI
2.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
Funders
  • MEXT | Japan Society for the Promotion of Science (17K09922, 20K08751)
  • MEXT | Japan Science and Technology Agency
  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation
  • Hori Sciences and Arts Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
cancer-associated fibroblasts, exosomes, lymphoma, ENT2, Rab27b, exosome secretion, tumor microenvironment, lymphoma cell survival, glycolysis, extracellular vesicles, microRNA
MeSH terms
Cancer-Associated Fibroblasts, Gemcitabine, Animals, Antimetabolites, Antineoplastic, Cytarabine, Deoxycytidine, Humans, Lymphoma, Male, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Equilibrative-Nucleoside Transporter 2, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Mice, Exosomes, Tumor Microenvironment, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. https://app.cochat.ai/papers/10.1038/s41388-021-01829-y
The paper
Kunou, S., Shimada, K., Takai, M., Sakamoto, A., Aoki, T., Hikita, T., Kagaya, Y., Iwamoto, E., Sanada, M., Shimada, S., Hayakawa, F., Oneyama, C., & Kiyoi, H. (2021). Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene. https://doi.org/10.1038/s41388-021-01829-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.